Vascular Biogenics Ltd. (VBLT) Shares Up 7.4%
Vascular Biogenics Ltd. (NASDAQ:VBLT) shares shot up 7.4% during mid-day trading on Wednesday . The stock traded as high as $4.37 and last traded at $4.23, with a volume of 542,679 shares trading hands. The stock had previously closed at $3.94.
Several research firms have recently issued reports on VBLT. Zacks Investment Research cut shares of Vascular Biogenics from a “hold” rating to a “sell” rating in a report on Thursday, May 5th. Chardan Capital reiterated a “buy” rating on shares of Vascular Biogenics in a report on Tuesday, June 7th. Roth Capital reiterated a “buy” rating and issued a $22.00 price objective on shares of Vascular Biogenics in a report on Thursday, June 9th. HC Wainwright began coverage on shares of Vascular Biogenics in a report on Tuesday, June 28th. They issued a “buy” rating and a $11.00 price objective for the company. Finally, Piper Jaffray Cos. reiterated a “buy” rating and issued a $14.00 price objective on shares of Vascular Biogenics in a report on Tuesday, June 7th. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Vascular Biogenics has a consensus rating of “Buy” and an average target price of $16.50.
The firm has a 50 day moving average price of $4.12 and a 200 day moving average price of $3.64. The firm’s market capitalization is $97.95 million.
Vascular Biogenics (NASDAQ:VBLT) last issued its earnings results on Friday, May 13th. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, meeting the consensus estimate of ($0.21). On average, equities analysts predict that Vascular Biogenics Ltd. will post ($0.82) EPS for the current fiscal year.
Vascular Biogenics Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of first-in-class treatments for cancer. The Company’s program is based on its Vascular Targeting System (VTS) platform technology, which utilizes genetically targeted therapy to destroy newly formed, or angiogenic, blood vessels.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.